More and more drug makers are turning to reformulation to prolong
the lifecycle of their top sellers and protect precious revenue
from generic copies, as well as supplement dwindling pipelines.
According to a new report, pharmaceutical and biotech companies
have not fully exploited the potential outsourcing represents,
having only been adopted to a limited extent to date by companies.
Although patent expirations are set to increase the size of the
generic drug market, the impact of greater scrutiny from healthcare
policymakers means that generic manufacturers may make more drugs
but not necessarily more money.
Although there are a number of interesting new compounds in the
antibacterial pipeline, none of them are likely to reach
blockbuster status, according to a new report from Datamonitor.
A new report from Datamonitor predicts the end of the
pharmaceutical industry's blockbuster product model, pointing to a
dramatic shortfall in growth rates for billion dollar-plus products
out to 2008.
The pharmaceutical industry is failing to increase efficiencies in
core areas of its business - such as clinical trials and sales -
because of an enormous pressure from investors to drive revenues,
according to Datamonitor.
Women are becoming the most attractive target audience for
healthcare companies, claims a new report from market analysts
Datamonitor. A combination of increasing Internet access, a general
interest in health issues among women along...